Aligos Therapeutics, a Phase 1 biotech developing oligonucleotide therapies for viral and liver diseases, raised $150 million by offering 10 million shares at $15, within the range of $14 to $16.
Aligos Therapeutics plans to list on the Nasdaq under the symbol ALGS. J.P. Morgan, Jefferies, Piper Sandler and Cantor Fitzgerald acted as joint bookrunners on the deal.
